Ophthotech Corporation (ISEE)
(Delayed Data from NSDQ)
$1.43 USD
+0.08 (5.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.43 USD
+0.08 (5.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study
by Zacks Equity Research
The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential
by Zacks Equity Research
Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
by Zacks Equity Research
The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.
Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.
BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up
by Zacks Equity Research
Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.
New Strong Sell Stocks for August 18th
by Zacks Equity Research
CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.
Implied Volatility Surging for IVERIC bio (ISEE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
IVERIC bio (ISEE) Enters Overbought Territory
by Zacks Equity Research
IVERIC bio (ISEE) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
New Strong Sell Stocks for April 26th
by Zacks Equity Research
ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021
New Strong Sell Stocks for April 21st
by Zacks Equity Research
EXTN, PSXP, ISEE, OR, and QIWI have been added to the Zacks Rank #5 (Strong Sell) List on April 21, 2021
New Strong Sell Stocks for April 6th
by Zacks Equity Research
JOBS, BUD, EURN, ISEE, and KL have been added to the Zacks Rank #5 (Strong Sell) List on April 6, 2021
New Strong Sell Stocks for March 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
J&J (JNJ) Acquires Rights for Hemera Biosciences' Gene Therapy
by Zacks Equity Research
Johnson & Johnson's (JNJ) Janssen acquires rights to investigational gene therapy, HMR59, for the treatment of geographic atrophy.
IVERIC bio (ISEE) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Moving Average Crossover Alert: IVERIC bio
by Zacks Equity Research
IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Why IVERIC bio (ISEE) Stock Might be a Great Pick
by Zacks Equity Research
IVERIC bio (ISEE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 13th.
Top Ranked Momentum Stocks to Buy for May 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 12th.
New Strong Buy Stocks for May 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is the Options Market Predicting a Spike in IVERIC bio (ISEE) Stock?
by Zacks Equity Research
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
Why Is IVERIC bio (ISEE) Up 79.1% Since Last Earnings Report?
by Zacks Equity Research
IVERIC bio (ISEE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well
by Zacks Equity Research
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.